International Isotopes Inc. Announces Company Name Change to Radnostix, Inc.
MWN-AI** Summary
International Isotopes Inc., now rebranded as Radnostix, Inc., announced its name change effective immediately following the filing of a Certificate of Amendment in Texas. This strategic rebranding reflects the company's evolution from its original focus on irradiation and manufacturing of industrial radioisotope products, which began in 1995, to a broader emphasis on radioisotope applications, including theranostics.
In its transformation to Radnostix, the company aims to encompass a wider range of product segments, particularly in the high-demand areas of radioisotopes and theranostics. While the International Isotopes name will no longer serve as the flagship brand, the INIS designation will still be used for segments related to high energy sources, bulk radioisotopes, and stable isotopes. Key existing brands such as Radqual, Radvent, Easyfill, Benchmark, and PhanQual will continue to operate under the Radnostix umbrella.
CEO Shahe Bagerdjian emphasized that the name Radnostix better aligns with the company's mission to become a premier partner in the radioisotope and theranostics market. He reassured stakeholders that the operational and management structure remains intact, and the company’s commitment to quality and customer service continues unabated.
As part of this transition, Radnostix, Inc.'s common stock will continue to trade under the ticker symbol "INIS" on the OTCQB marketplace, with future announcements about potential ticker changes forthcoming. The name change does not require any action from shareholders regarding their stock certificates.
Overall, the rebranding to Radnostix signifies a fresh direction while building on the legacy of International Isotopes Inc., signaling the company's readiness to navigate new opportunities in its field.
MWN-AI** Analysis
The recent rebranding of International Isotopes Inc. to Radnostix, Inc. marks a significant strategic pivot for the company, aimed at enhancing its position in the growing markets for radioisotopes and theranostics. This rebranding reflects the company's intent to adapt to evolving market conditions and customer needs.
Investors should closely monitor Radnostix's transition to this new branding, as it symbolizes a broader shift in focus while maintaining the established operational framework. The company has been operational since 1995, which adds a layer of stability and experience in a field that requires rigorous regulatory compliance and innovative product offerings.
Radnostix's diverse portfolio—including generic sodium iodide I-131, contract manufacturing, calibration standards, and Cobalt-60 products—positions it well for growth in a healthcare environment increasingly prioritizing personalized medicine and targeted therapies. The shift toward theranostics, which combines diagnostics with therapeutics, aligns with broader trends in the biopharmaceutical space and presents an opportunity for Radnostix to capture market share.
From a market perspective, potential investors should consider the implications of the company’s rebranding on its stock performance. While the ticker "INIS" remains unchanged for the moment, a future name-associated ticker could stimulate renewed investor interest and visibility. The proactive communication from management regarding strategic directions indicates transparency, which is a positive signal for investor confidence.
However, as with any investment, caution is advised. Radnostix operates in a highly regulated sector that is subject to market fluctuations, technological advancements, and competitive pressures. Monitoring their operational adjustments and market responses will be crucial in evaluating their financial health moving forward. As such, interested investors should keep a close eye on upcoming announcements and the company’s quarterly performance in the context of its rebranding initiatives.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
PR Newswire
IDAHO FALLS, Idaho, Dec. 31, 2025 /PRNewswire/ -- International Isotopes Inc. ("INIS" or the "Company") (OTCQB:INIS) today announced that it has filed a Certificate of Amendment in the State of Texas to change our legal name to Radnostix, Inc. Effective immediately, we will officially begin to rebrand all of our operations under the Radnostix name. INIS was started in 1995 as a company focused on irradiation and manufacturing of industrial radioisotope products. Over the years, our focus has evolved, and the name change reflects the Company's expanding product segments and evolving strategic focus on radioisotopes and theranostics products.
While the International Isotopes Inc. branding will no longer be our flagship, the INIS branding will be re-utilized around our segments which are focused on high energy sources, bulk radioisotopes, and stable isotopes. Our other brands, Radqual, Radvent, Easyfill, Benchmark, and PhanQual, will continue going forward under the umbrella of Radnostix, Inc. The Company's operations, management team, and commitment to its customers and partners remain unchanged.
"The name Radnostix better encapsulates our mission to become the premiere industry partner in the radioisotope & theranostics space. While our name is changing, our dedication to quality, innovation, and customer service and our strategic direction remain steadfast" said Radnostix CEO, Shahe Bagerdjian.
At this time, the Company's common stock will continue to trade under its current ticker symbol "INIS" on the OTCQB marketplace. Further information regarding a potential new ticker symbol, if any, will be announced in due course. Shareholders are not required to take any action regarding their stock certificates as a result of the name change.
About Radnostix (formerly International Isotopes Inc.): Radnostix, Inc. (formerly International Isotopes Inc.) (INIS), established in 1995, with its headquarters in Idaho Falls, ID, USA, manufactures a wide range of radioisotope-focused products. Radnostix manufactures and supplies generic sodium iodide I-131 radio-pharmaceutical drug product for hyperthyroidism and thyroid cancer. Radnostix provides contract manufacturing of various drug products as well as radioisotope API supply for 3rd party theranostics clients. Radnostix manufactures and distributes a complete line of calibration and reference standards for nuclear pharmacies and SPECT/PET imaging systems as well as industrial calibration standards under its RadQual brand. The Company also manufactures Cobalt-60 sealed source products. For more information, visit radnostix.com.
Radnostix, Inc. (formerly International Isotopes Inc.) Safe Harbor Statement:
Certain statements in this press release are "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements with respect to the Company's future growth expectations. Information contained in such forward-looking statements is based on current expectations and is subject to change. These statements involve a number of risks, uncertainties and other factors that could cause actual results, performance, or achievements of Radnostix, Inc. to be materially different from any future results, performance or achievements of the Company expressed or implied by these forward-looking statements. Other factors, which could materially affect such forward-looking statements, can be found in the Company's filings with the Securities and Exchange Commission at www.sec.gov, including its Annual Report on Form 10-K for the year ended December 31, 2024. Investors, potential investors, and other readers are urged to consider these factors carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such forward-looking statements. The forward-looking statements made herein are only made as of the date of this press release and Radnostix, Inc. and the Company undertake no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.
Radnostix Contact:
ir@intisoid.com
radnostix.com
intisoid.com
208.524.5300
Investor Relations Contact:
David Drewitz, Creative
Options Communications Investor and Public Relations
david@creativeoptionscommunications.com
creativeoptionsmarketing.com
972.814.5723
SOURCE International Isotopes Inc.
FAQ**
How will the name change from International Isotopes Inc INIS to Radnostix, Inc. impact the company's branding strategy and market positioning in the radioisotope and theranostics sector?
What specific product segments does Radnostix, Inc. plan to focus on post-rebranding that signifies a shift from International Isotopes Inc INIS's original business model?
Can Radnostix, Inc. provide insights on how the name change affects its existing partnerships and customer relationships previously established under International Isotopes Inc INIS?
What are the anticipated financial implications of the rebranding for Radnostix, Inc. compared to the historical performance of International Isotopes Inc INIS, particularly regarding growth and investment opportunities?
**MWN-AI FAQ is based on asking OpenAI questions about International Isotopes Inc (OTC: INIS).
NASDAQ: INIS
INIS Trading
8.7% G/L:
$0.07 Last:
3,301 Volume:
$0.09 Open:
